PHKA2-AS1: A Potential Drug Target and Biomarker (G100132163)

Target Name: PHKA2-AS1

NCBI ID: G100132163

PHKA2-AS1

Other Name(s): PHKA2 antisense RNA 1

PHKA2-AS1: A Potential Drug Target and Biomarker

PHKA2-AS1, also known as AS1-100, is a protein that is expressed in the endoplasmic reticulum (ER) and is involved in the regulation of the cytoskeleton. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of PHKA2-AS1 as a potential drug target and biomarker comes from a study by the research group led by Dr. Xujiong Ye at the University of California, San Diego. The study, published in the journal Nature Communications, identified PHKA2-AS1 as a key regulator of the cytoskeleton and a potential drug target for neurodegenerative diseases.

PHKA2-AS1 is a protein that is composed of 256 amino acids and has a molecular weight of 31 kDa. It is located in the endoplasmic reticulum and is involved in the regulation of the cytoskeleton, which is the structure that gives shape to the cell. The cytoskeleton is responsible for the maintenance of cell shape, stability, and movement.

PHKA2-AS1 is a key regulator of the cytoskeleton because it helps to regulate the distribution of organelles in the cell. It does this by interacting with other proteins that are involved in the cytoskeleton, including the protein known as T-complex. The T-complex is a protein that is involved in the regulation of the cytoskeleton and is composed of the proteins T-type cytoskeleton protein (T-CF) and the protein known as p180.

PHKA2-AS1 is also involved in the regulation of the cytoskeleton because it helps to control the dynamics of the cytoskeleton. This is done by interacting with other proteins that are involved in the cytoskeleton, including the protein known as N-cadherin. N-cadherin is a protein that is involved in cell-cell adhesion and is composed of two subunits.

PHKA2-AS1 is a potential drug target for neurodegenerative diseases because it is involved in the regulation of the cytoskeleton and is a key regulator of the cytoskeleton. This suggests that if a drug can inhibit the activity of PHKA2-AS1, it may be effective in treating neurodegenerative diseases.

PHKA2-AS1 is also a potential biomarker for neurodegenerative diseases because it is involved in the regulation of the cytoskeleton and is a key regulator of the cytoskeleton. This suggests that if the level of PHKA2-AS1 is decreased in the brain, it may be a sign of neurodegenerative disease.

In conclusion, PHKA2-AS1 is a protein that is involved in the regulation of the cytoskeleton and has the potential to be a drug target and biomarker for various neurodegenerative diseases. Further research is needed to fully understand the role of PHKA2-AS1 in neurodegenerative diseases and to develop effective treatments.

Protein Name: PHKA2 Antisense RNA 1

The "PHKA2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHKA2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets